Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Liabilities (2016 - 2025)

VYNE Therapeutics filings provide 10 years of Total Liabilities readings, the most recent being $2.4 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 83.84% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 83.84% decrease, with the full-year FY2025 number at $2.4 million, down 83.84% from a year prior.
  • Total Liabilities hit $2.4 million in Q4 2025 for VYNE Therapeutics, down from $5.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $59.1 million in Q2 2021 to a low of $2.4 million in Q4 2025.
  • Median Total Liabilities over the past 5 years was $9.0 million (2023), compared with a mean of $15.2 million.
  • Biggest five-year swings in Total Liabilities: tumbled 88.43% in 2022 and later skyrocketed 65.58% in 2024.
  • VYNE Therapeutics' Total Liabilities stood at $18.4 million in 2021, then crashed by 49.24% to $9.3 million in 2022, then dropped by 4.23% to $9.0 million in 2023, then soared by 65.58% to $14.8 million in 2024, then plummeted by 83.84% to $2.4 million in 2025.
  • The last three reported values for Total Liabilities were $2.4 million (Q4 2025), $5.8 million (Q2 2025), and $12.3 million (Q1 2025) per Business Quant data.